The HIV estimates accuracy tool is an end user application that uses statistical methods to calculate adjusted estimates from HIV surveillance data taking into account the issues of missing data and reporting delay.
With nearly 160 000 people newly diagnosed with HIV, 2017 marked another year of alarming numbers of new HIV diagnoses in the WHO European Region. In contrast, the European Union and European Economic Area (EU/EEA) countries reported a decline in rates of new diagnoses, mainly driven by a 20% decrease since 2015 among men who have sex with men.
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens?